10-QPeriod: Q1 FY2025

CVS HEALTH Corp Quarterly Report for Q1 Ended Mar 31, 2025

Filed May 1, 2025For Securities:CVS

Summary

CVS Health Corporation reported solid top-line growth in the first quarter of 2025, with total revenues increasing by 7.0% year-over-year to $94.6 billion. This growth was broad-based across its segments, driven by higher product and premium revenues. The company demonstrated significant improvement in operating income, which surged by 48.6% to $3.4 billion, largely due to favorable prior-year development and improved performance in its Health Care Benefits segment, partially offset by one-time charges including a $387 million litigation charge related to the Omnicare verdict and a $247 million loss on Accountable Care assets. Net income attributable to CVS Health also saw a substantial increase of 59.8% to $1.8 billion, resulting in diluted earnings per share of $1.41, a significant improvement from $0.88 in the prior year. Despite the strong profitability, the company noted a decline in its Medicare and individual exchange medical membership. Management highlighted continued pressure from utilization in its Health Care Benefits segment and a cautious outlook regarding potential future premium deficiency reserves. The company also reported strong cash flow from operations and a healthy cash position, while managing its debt levels and continuing its share repurchase program.

Financial Highlights

53 data points
Beta

Revenue

$94.59B

46.0% Gross Margin

Net Income

$1.78B

1.9% Net Margin

EPS (Diluted)

$1.41

Total Assets

$255.59B

Cash & Equivalents

$10.08B

Free Cash Flow

$3.81B

Financial Statements
Beta
Revenue$94.59B
Cost of Revenue$51.06B
Gross Profit$43.53B
Operating Expenses$91.21B
Operating Income$3.37B
Net Income$1.78B
EPS (Basic)$1.41
EPS (Diluted)$1.41
Shares Outstanding (Basic)1.26B
Shares Outstanding (Diluted)1.26B

Key Highlights

  • 1Total revenues grew 7.0% to $94.6 billion, driven by increases in product and premium revenues across segments.
  • 2Operating income surged by 48.6% to $3.4 billion, primarily due to favorable prior-year development and improved Medicare performance.
  • 3Net income attributable to CVS Health increased by 59.8% to $1.8 billion, with diluted EPS rising to $1.41 from $0.88.
  • 4A $448 million premium deficiency reserve was recorded for the individual exchange product line, impacting the Health Care Benefits segment.
  • 5The company is exiting the ACO REACH program and divested its MSSP operations, resulting in a $247 million loss on Accountable Care assets.
  • 6Medical membership in Medicare and individual exchange products declined, though overall medical membership remained relatively stable year-over-year.
  • 7Cash flow from operating activities was $4.6 billion, with the company maintaining a strong liquidity position.

Frequently Asked Questions

The substantial increase in operating income of 48.6% to $3.4 billion was primarily driven by favorable year-over-year impacts from prior-year development and improved underlying performance in the Medicare Advantage program. Additionally, the absence of a $100 million opioid litigation charge from the prior year contributed to the increase. These positive factors were partially offset by specific charges, including a $387 million litigation charge related to the Omnicare jury verdict and a $247 million pre-tax loss on Accountable Care assets recorded in the current quarter.

During the first quarter of 2025, CVS Health recorded a $448 million premium deficiency reserve related to its individual exchange product line for the 2025 coverage year. This reserve consists of $17 million in operating expenses (write-off of unamortized acquisition costs) and $431 million in health care costs. This significantly impacted the Health Care Benefits segment's results.

CVS Health maintains a strong liquidity position, with $10.1 billion in cash and cash equivalents as of March 31, 2025. Net cash provided by operating activities was $4.6 billion for the quarter. The company's financing activities included lower net proceeds from commercial paper borrowings and higher repayments of long-term debt compared to the prior year. The company also has significant authorized share repurchase programs in place, though no shares were repurchased in the current quarter.

Key trends and uncertainties include continued elevated utilization in the Health Care Benefits segment, which may lead to additional premium deficiency reserves. The Medicaid business is experiencing medical cost pressures following member redeterminations. The company also notes ongoing pressures related to sharing rebates with clients and potential impacts from regulatory changes and competitive dynamics in the PBM and retail pharmacy sectors. Management also expects benefits from enterprise-wide cost savings initiatives.